Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial

By afschroeder • February 7, 2026

Landon BV, Boland JL, Wahner Hendrickson AE, Armstrong DK, Winterhoff B, Wehr J, Annapragada AV, Cherry C, Balan A, Kaleka G, Velculescu VE, Baylin SB, Zahnow CA, Slamon DJ, Konecny GE, Anagnostou V, Glaspy JA. Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial. Commun Med (Lond). 2026 Feb 6. doi: 10.1038/s43856-026-01404-0. Epub ahead of print. PMID: 41652014.

Tags: Fellow, Hematology/Oncology, Olive View DoM, Publications

Autosomal allelic inactivation at loci with variable replication timing and dosage sensitivity

Heskett MB, Vouzas AE, Johnstone B, Freese KP, Yates PA, Copenhaver PF, Spellman PT, Gilbert DM, Thayer MJ. Autosomal allelic inactivation at loci with variable[...]

A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma)

Shin SJ, Lee JL, Powles T, Martin-Liberal J, Morales-Barrera R, Drakaki A, Friedlander T, Joly F, Shah SA, Vuky J, Ianculescu I, Michielin F, Gan[...]

The Association Between Healthcare Provider Trust and Healthcare Avoidance: Findings From a HIV Mixed Serostatus Cohort Study

Singleton M, Plankey M, Bowleg L, Brock JB, Haberlen S, Jamieson BD, Kempf MC, Konkle-Parker DJ, Kwait J, Martinson J, Mimiaga MJ, Ramirez CM, Stosor[...]